Philipp Störmann1, William Osinloye2, Thomas M Freiman3, Volker Seifert3, Ingo Marzi2, Thomas Lustenberger2. 1. Department of Trauma, Hand and Reconstructive Surgery, Hospital of the Johann Wolfgang Goethe - University Frankfurt Am Main, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. philipp.stoermann@kgu.de. 2. Department of Trauma, Hand and Reconstructive Surgery, Hospital of the Johann Wolfgang Goethe - University Frankfurt Am Main, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. 3. Department of Neurosurgery, Hospital of the Johann Wolfgang Goethe - University Frankfurt Am Main, Schleusenweg 2, 60528, Frankfurt, Germany.
Abstract
BACKGROUND: Venous thromboembolism (VTE) is recognized as a factor of morbidity and mortality in trauma patients suffering from severe blunt traumatic brain injury (TBI). The administration of pharmacological prophylaxis is broadly accepted as an effective therapy to prevent VTE events in trauma patients. Regardless of its ascertained efficacy, the risk of hematoma progression complicates the therapy in patients suffering from TBI: therefore, the optimal time to start prophylactic anticoagulation in these patients remains controversial. METHODS: All primary admissions to our level-1-trauma center between January 2012 and December 2016 were screened for severe blunt TBI with a head Abbreviated Injury Scale (AIS) ≥ 3. Patients who died within the first 24 h were excluded. Basic demographic results, thromboembolic events and progression of the intracranial hematoma were extracted from the patient's records. The patients were categorized into 4 groups according to start of VTE chemoprophylaxis: early ( < 24 h after hospitalization), intermediate (24-48 h), late ( > 48 h) and no therapy (no prophylactic anticoagulation within the first five days of hospitalization). A total of 292 patients with severe TBI were analyzed (early: n = 93, intermediate: n = 90, late: n = 74, no therapy: n = 35). The overall rate of intracranial bleeding progression was 13.6% after prophylactic anticoagulation was started. RESULTS: No statistically significant differences were found in the frequency of intracranial bleeding progression comparing the different time groups (early 12.9% vs. intermediate 11.1% vs. late 17.6%; adj. p = 0.13). In patients with VTE chemoprophylaxis, no thromboembolic events were recorded. Male gender, age, head AIS and subarachnoidal hemorrhage were identified as independent risk factors associated with intracranial hematoma progression. CONCLUSION: The early administration of VTE chemoprophylaxis within 24 h after admission in patients with severe TBI did not increase the risk of intracranial bleeding progression.
BACKGROUND:Venous thromboembolism (VTE) is recognized as a factor of morbidity and mortality in traumapatients suffering from severe blunt traumatic brain injury (TBI). The administration of pharmacological prophylaxis is broadly accepted as an effective therapy to prevent VTE events in traumapatients. Regardless of its ascertained efficacy, the risk of hematoma progression complicates the therapy in patients suffering from TBI: therefore, the optimal time to start prophylactic anticoagulation in these patients remains controversial. METHODS: All primary admissions to our level-1-trauma center between January 2012 and December 2016 were screened for severe blunt TBI with a head Abbreviated Injury Scale (AIS) ≥ 3. Patients who died within the first 24 h were excluded. Basic demographic results, thromboembolic events and progression of the intracranial hematoma were extracted from the patient's records. The patients were categorized into 4 groups according to start of VTE chemoprophylaxis: early ( < 24 h after hospitalization), intermediate (24-48 h), late ( > 48 h) and no therapy (no prophylactic anticoagulation within the first five days of hospitalization). A total of 292 patients with severe TBI were analyzed (early: n = 93, intermediate: n = 90, late: n = 74, no therapy: n = 35). The overall rate of intracranial bleeding progression was 13.6% after prophylactic anticoagulation was started. RESULTS: No statistically significant differences were found in the frequency of intracranial bleeding progression comparing the different time groups (early 12.9% vs. intermediate 11.1% vs. late 17.6%; adj. p = 0.13). In patients with VTE chemoprophylaxis, no thromboembolic events were recorded. Male gender, age, head AIS and subarachnoidal hemorrhage were identified as independent risk factors associated with intracranial hematoma progression. CONCLUSION: The early administration of VTE chemoprophylaxis within 24 h after admission in patients with severe TBI did not increase the risk of intracranial bleeding progression.
Authors: Kent Denson; Daniel Morgan; Rob Cunningham; Anthony Nigliazzo; Daniel Brackett; Mary Lane; Brenda Smith; Roxie Albrecht Journal: Am J Surg Date: 2007-03 Impact factor: 2.565
Authors: Markus B Skrifvars; Michael Bailey; Jeffrey Presneill; Craig French; Alistair Nichol; Lorraine Little; Jacques Duranteau; Olivier Huet; Samir Haddad; Yaseen Arabi; Colin McArthur; D James Cooper; Rinaldo Bellomo Journal: Intensive Care Med Date: 2016-12-27 Impact factor: 17.440
Authors: Yamaan Saadeh; Kartik Gohil; Charles Bill; Curtis Smith; Chet Morrison; Benjamin Mosher; Paul Schneider; Penny Stevens; John P Kepros Journal: J Trauma Acute Care Surg Date: 2012-08 Impact factor: 3.313
Authors: A Kleindienst; H B Harvey; E Mater; J Bronst; J Flack; K Herenz; W F Haupt; R Schön Journal: Acta Neurochir (Wien) Date: 2003-11-03 Impact factor: 2.216
Authors: Rachel A Pastorek; Michael W Cripps; Ira H Bernstein; William W Scott; Christopher J Madden; Kim L Rickert; Steven E Wolf; Herb A Phelan Journal: J Neurotrauma Date: 2014-08-28 Impact factor: 5.269
Authors: Fabio A Frisoli; Matthew Shinseki; Lynda Nwabuobi; Xiaopei L Zeng; Murillo Adrados; Carolyn Kanter; Spiros G Frangos; Paul P Huang Journal: Neurosurgery Date: 2017-12-01 Impact factor: 4.654
Authors: Eric J Ley; Carlos V R Brown; Ernest E Moore; Jack A Sava; Kimberly Peck; David J Ciesla; Jason L Sperry; Anne G Rizzo; Nelson G Rosen; Karen J Brasel; Rosemary Kozar; Kenji Inaba; Matthew J Martin Journal: J Trauma Acute Care Surg Date: 2020-11 Impact factor: 3.313
Authors: Joseph F Rappold; Forest R Sheppard; Samuel P Carmichael Ii; Joseph Cuschieri; Eric Ley; Erika Rangel; Anupamaa J Seshadri; Christopher P Michetti Journal: Trauma Surg Acute Care Open Date: 2021-02-24
Authors: Navpreet K Dhillon; Yassar M Hashim; Naomi Berezin; Felix Yong; Geena Conde; Russell Mason; Eric J Ley Journal: Trauma Surg Acute Care Open Date: 2021-05-10